Home › Compare › DIGTF vs ABBV
DIGTF yields 18181.82% · ABBV yields 3.12%● Live data
📍 DIGTF pulled ahead of the other in Year 1
Combined, DIGTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DIGTF + ABBV for your $10,000?
Thruvision Group plc engages in development, manufacture, and sale of passive people-screening technology in the United Kingdom, rest of Europe, the Americas, the Asia-Pacific, the Middle East, and Africa. The company provides surface transportation security cameras for protecting the traveling public from terrorist attack; customs and border security cameras to check travelers for concealed contraband; entrance and public venue security cameras for screening visitors to detect weapons and explosives; loss prevention security cameras to detect and deter theft; and deployment accessories to provide operational flexibility. Its products are used in aviation security, retail supply chain loss prevention, customs and border control, and public area security. The company was formerly known as Digital Barriers plc and changed its name to Thruvision Group plc in November 2017. Thruvision Group plc was incorporated in 2010 and is headquartered in Abingdon, the United Kingdom.
Full DIGTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.